.jpg "Meniscus Replacement: What the Procedure Involves, Who It Helps, and What Research Actually Shows")
World At Net · Health & Medicine
Most people are barely aware the meniscus exists until something goes wrong with it. It is not a bone, and it does not show up on standard X-rays. It is a pair of fibrocartilage structures inside the knee, one on the inner side and one on the outer side, each shaped roughly like a crescent moon.
Together, they cushion the joint, distribute load, assist with rotational stability, and keep the femur from grinding directly into the tibia. They do all of this silently, during every step, every squat, every landing, for decades. When they tear or deteriorate beyond repair, the consequences for the knee are significant and, if untreated, often progressive.
Meniscal injuries are among the most common knee problems in orthopaedic practice worldwide. Arthroscopic surgery of the knee is the most common type of knee surgery with an estimated close to a million procedures per year in the United States, and arthroscopic partial meniscectomy, the removal of damaged meniscal tissue, represents the most frequently performed of those procedures.
For many years, removing the damaged portion and moving on was considered a reasonable solution. We now know it is not quite as simple as that. Losing meniscal tissue has measurable long-term consequences for joint health, and the field of orthopaedic surgery has spent the last two decades developing techniques to replace or reconstruct what is lost.
This article explores those techniques in detail, drawing on the most current peer-reviewed evidence available.
Understanding why meniscus replacement matters requires understanding what the meniscus actually does. Each knee contains a medial meniscus on the inside and a lateral meniscus on the outside.
Both are made of fibrocartilage, a tough material combining the tensile strength of collagen with the compressive resistance of cartilage. Together they cover roughly 60 to 70 percent of the contact surface between the femur above and the tibia below. When you stand or walk, your body weight passes through the knee joint.
The menisci spread that load across a wider surface area, reducing the peak stress on any single point of the articular cartilage that lines the joint surfaces. Without them, contact stresses rise sharply, and articular cartilage begins to wear.
Beyond load distribution, the menisci serve as secondary stabilizers of the knee, particularly in rotation, and they contain nerve endings that contribute to proprioception, the body's sense of where the joint is in space. They also play a role in joint lubrication and in guiding the natural rolling and gliding motion of the femur on the tibia during flexion and extension.
In short, they are not passive shock absorbers. They are dynamic, multifunctional structures whose absence the knee feels keenly over time.
Tears occur in two main ways. In younger, athletic individuals, they typically result from trauma, a sudden twist, a forceful pivot, or direct contact during sport. In middle-aged and older adults, degenerative tears are more common, developing gradually as the tissue loses elasticity and strength over time.
The blood supply within the meniscus is limited to its outer periphery, a region called the red zone, where healing is possible. The inner portion, the white zone, is avascular and cannot heal on its own. The location of the tear relative to these zones is one of the key factors determining whether repair is feasible or whether some degree of tissue removal becomes necessary.
For many years, removing damaged meniscal tissue was treated as a relatively minor consequence of addressing a painful tear. The prevailing assumption was that partial meniscectomy, clearing out the torn portion, would relieve symptoms without creating significant problems down the line.
Long-term research has since made clear that this view was overly optimistic. A landmark study published in the Journal of Bone and Joint Surgery found that surgical removal of a meniscus represented a significant risk factor for radiographic tibiofemoral osteoarthritis, with a relative risk of 14.0 after 21 years of follow-up, compared to matched controls with healthy knees.
More recent data reinforces this picture. A systematic review published in 2024 found that meniscectomy patients showed a 51.42 percent progression rate toward osteoarthritis, significantly higher than the 21.28 percent observed in patients who had undergone meniscal repair instead.
Functional outcomes were also better in the repair group across multiple validated scoring tools. These findings have driven a fundamental shift in how surgeons think about the meniscus. The philosophy is no longer removal and acceptance. It is preservation wherever possible, and replacement when preservation is no longer an option.
"The concept of meniscal preservation has progressed over the years: nonoperative management of degenerative lesions, repair of some traumatic tears, and meniscus replacement if indicated."EU-US Meniscus Rehabilitation Consensus, ESSKA-AOSSM-AASPT 2024
A subset of patients who have already undergone meniscectomy develop what clinicians call post-meniscectomy syndrome. This is a condition characterized by persistent joint line pain, mechanical symptoms, and a sense of instability, often appearing months or years after the original surgery.
The increased contact stress within the joint, no longer moderated by the absent meniscal tissue, causes ongoing damage. For these patients, if advanced osteoarthritis has not yet set in, meniscal replacement surgery becomes the primary treatment pathway.
When meniscal tissue has been lost to an extent that makes repair impossible, two distinct surgical strategies are available. The choice between them depends on how much tissue has been removed. If part of the meniscus remains, a scaffold implant can fill and support the deficient area while the body regenerates tissue within it.
If the meniscus is substantially or totally absent, a meniscal allograft transplantation, using real donor tissue, becomes the appropriate option. Neither approach is suitable for every patient, and the decision involves careful consideration of age, activity level, cartilage condition, knee alignment, and the degree of tissue loss.
A real meniscus from a cadaver donor is sized, prepared, and surgically implanted to replace the absent tissue. The gold standard for patients with functionally deficient meniscus following meniscectomy.
A biocompatible implant, either collagen-based or synthetic polyurethane, is placed in the area of tissue deficiency to act as a scaffold for new tissue ingrowth. Suitable when meaningful meniscal rim remains.
Meniscal allograft transplantation is the most established surgical option for patients who have lost the majority of their meniscal tissue. The procedure uses a meniscus obtained from a deceased donor, preserved either by freezing or, in newer approaches, kept fresh for viable cell transplantation.
The donor graft is sized to match the recipient's knee using MRI measurements and tibial plateau dimensions, because a graft that is too large or too small will not sit correctly in the joint and is more likely to fail.
The surgical technique involves arthroscopic or arthroscopic-assisted implantation. Most surgeons use a technique that anchors the graft through bone fixation, either with bone plugs attached to the anterior and posterior horns of the graft or using a bone bridge technique that slots into a trough cut in the tibial plateau. A third approach uses soft-tissue suture fixation alone, without bone blocks, and is preferred in certain anatomical situations.
The peripheral rim of the graft is then sutured to the capsule of the knee to restore the circumferential and radial fiber orientation that allows the meniscus to bear load effectively.
A major 2024 review of long-term MAT outcomes published in Current Reviews in Musculoskeletal Medicine reported graft survivorship of approximately 80 percent at 10 years, with return to sport rates exceeding 70 percent. The majority of patients reached established thresholds for clinically meaningful improvement.
The same review noted that cartilage damage at the time of surgery increases the risk of graft failure, though this risk can be partially offset by performing a concurrent cartilage restoration procedure such as microfracture or osteochondral grafting.
A study from the University of Missouri, published in 2024, assessed fresh (viable cell) meniscus allografts in 45 patients over a mean follow-up of nearly four years. Using a double bone plug suspensory fixation technique with meniscotibial ligament reconstruction, the procedure was associated with a 91 percent success rate, with no local or systemic adverse events or complications related to the transplantation reported for any patient in the study.
The typical candidate for MAT is younger than 50, has a history of subtotal or total meniscectomy, maintains a body mass index below 35, has articular cartilage changes of no worse than grade 2, and has acceptable or correctable knee alignment and stability.
Lateral MAT generally produces better clinical outcomes and lower failure risk compared to medial MAT, likely because the lateral compartment has a more forgiving biomechanical environment. Midterm survivorship is reported as 85 to 90 percent, though long-term survivorship over 15 to 20 years decreases to 50 to 70 percent depending on cartilage status and whether additional procedures were performed at the same time.
One finding that initially concerned surgeons, meniscal extrusion, where the graft migrates slightly outward from its intended position on the tibial plateau, has been found in multiple studies to be common after MAT but does not appear to significantly alter clinical results. Significant improvements in patient-reported outcomes are expected following MAT, and 90 percent of patients report they would undergo the procedure again.
| Outcome Measure | MAT Result | Source / Notes |
|---|---|---|
| 10-Year Graft Survivorship | ~80% | Phillips et al., PubMed 2024 |
| Return to Sport Rate | >70% | Phillips et al., PubMed 2024 |
| Patient Satisfaction (Would Repeat) | 90% | ScienceDirect Systematic Review |
| Fresh Graft Success Rate | 91% | Cook et al., University of Missouri 2024 |
| Reoperation Rate | ~32% | ScienceDirect Meta-Analysis |
| Mean Time to Failure (Medial) | ~8.2 years | ScienceDirect Systematic Review |
| Long-Term Survivorship (15-20 yr) | 50 to 70% | PMC Review, varies by cartilage status |
For patients who still have a functional peripheral meniscal rim but have lost substantial tissue in the inner body, scaffold implantation offers an alternative to full allograft transplantation.
The scaffold is inserted arthroscopically into the deficient region and sutured to the remaining meniscal tissue. Over the following months, fibrochondrocytes from the surrounding tissue migrate into the scaffold, deposit new extracellular matrix, and gradually replace the implant with biologically functional tissue.
The scaffold itself either biodegrades over time or becomes incorporated into the new tissue depending on its composition.
Three scaffold products have accumulated the most clinical data. The Collagen Meniscus Implant, known as CMI and marketed under the Menaflex brand by Stryker, is derived from bovine Achilles tendon collagen type I and is enriched with glycosaminoglycans including chondroitin sulfate and hyaluronic acid. It closely mimics the biochemical environment of native meniscal tissue.
The Actifit scaffold, produced by Orteq, is a synthetic polyurethane-based implant composed of 80 percent polycaprolactone and 20 percent polyurethane, reinforced with ultrahigh molecular weight polyethylene fibers for structural support.
The NUsurface implant from Active Implants is made of medical-grade polycarbonate urethane and functions slightly differently, acting more as a load-distributing spacer than a tissue-regenerating scaffold.
A systematic review found failure rates for Actifit of 18 percent at a mean follow-up of approximately 67 months, and for CMI of 6.5 percent at a mean follow-up of around 97 months. Both products produced significant improvements in validated knee scores including the Lysholm score, IKDC score, and visual analog pain scale compared to preoperative baselines.
A comparative study of collagen versus synthetic scaffolds found CMI Lysholm scores improving from 58.4 to 94.5 and Actifit scores improving from 67.0 to 90.3, with both improvements statistically significant and without a significant difference between groups at final follow-up.
- CMI is preferred for partial medial or lateral deficiency with healthy vascular rim tissue
- Actifit is suitable for larger defects including lateral meniscus and for patients where tissue ingrowth potential may be lower
- NUsurface is typically reserved for patients with medial compartment pain and partial tissue loss who are not candidates for allograft
- A minimum viable peripheral rim of 3 to 5 mm is required for scaffold suturing
- Advanced articular cartilage damage (grade 3 or 4) significantly reduces scaffold success rates
- Patient age below 50 and BMI below 35 are preferred criteria across all scaffold types
The field has also seen early work on three-dimensional printed scaffolds, which offer the theoretical advantage of being customized to an individual patient's exact anatomy.
This remains an experimental treatment with only a few case reports available at present, but it represents the direction in which meniscal scaffold technology is heading as additive manufacturing and bioprinting become more sophisticated in orthopaedic applications.
Both MAT and scaffold implantation work best when they are performed in appropriately selected patients. Choosing the wrong patient for either procedure significantly reduces the likelihood of a good outcome, and the published data that supports these techniques comes almost entirely from populations that were carefully screened before surgery.
Understanding the criteria is therefore central to understanding what the research actually demonstrates.
For meniscal allograft transplantation, the ideal candidate is typically under 50 years of age, though many surgeons extend this to 55 in active patients without significant cartilage loss. The patient should have persistent knee pain, mechanical symptoms, or functional limitation that has not responded to conservative management including physiotherapy, activity modification, and pain management.
There should be a documented history of previous meniscectomy of sufficient extent to cause biomechanical disruption. Crucially, the articular cartilage should be intact or show only low-grade changes. Significant malalignment of the lower limb, meaning the knee does not bear weight in a neutral mechanical axis, must be addressed either prior to or concurrently with the transplant, as continued varus or valgus loading will accelerate graft failure. Active infection and inflammatory arthritis are contraindications.
For scaffold implantation, the patient must have a sufficient peripheral meniscal rim remaining for secure suture fixation. If too little rim tissue remains, the scaffold cannot be anchored and will fail.
The patient should be symptomatic from the meniscal deficiency rather than from another source of knee pain, and the articular cartilage grading should ideally be no worse than grade 2 on the Outerbridge or International Cartilage Repair Society scale. Higher-grade chondral damage dramatically reduces the benefit of scaffold implantation and may push the clinical decision toward allograft or toward a combined procedure.
"Graft survivorship is approximately 80 percent at 10 years, significantly delaying and in some cases preventing the need for future joint reconstruction procedures in these young, active patients."Phillips et al., Current Reviews in Musculoskeletal Medicine, PubMed 2024
Meniscal allograft transplantation is performed under general or spinal anaesthesia with the patient positioned to allow full arthroscopic access to the knee.
The procedure begins with a diagnostic arthroscopy to confirm the joint environment and assess cartilage status directly. Any remaining meniscal tissue is prepared, and the bone bed at the anterior and posterior horn attachment sites on the tibial plateau is shaped to receive the graft. In the bridge-in-slot technique, a shallow trough is cut across the tibia connecting the two horn sites, and the bone bridge on which the donor graft's horns are attached slides into this prepared slot.
The graft is sized from donor tissue matched to the recipient's MRI measurements with typical accuracy within a few millimetres. Once the bone fixation is secured, the peripheral edge of the meniscal allograft is sutured to the capsule and remaining rim tissue using inside-out, outside-in, or all-inside suture techniques depending on the location being repaired and the surgeon's preference.
Final arthroscopic assessment confirms graft position, tension, and integration. Most patients require an overnight hospital stay, though some centers perform the procedure as a day case depending on the complexity and any concurrent procedures.
Scaffold implantation follows a similar arthroscopic approach. Once the decision to implant is confirmed by direct visualization of the meniscal defect, the remaining tissue edges are prepared to create a stable base for suturing. The scaffold is sized to the defect, trimmed if needed, and sutured into position using the same techniques applied in meniscal repair.
The key technical objective is creating a watertight integration between the scaffold and the residual native tissue so that joint fluid, which contains growth factors and nutrients, can permeate the implant and support tissue ingrowth. The procedure typically lasts between 45 and 90 minutes depending on concurrent procedures being performed.
Recovery after meniscal replacement surgery is longer than many patients anticipate, and the rehabilitation protocol plays a significant role in determining the final outcome. The 2024 EU-US Meniscus Rehabilitation Consensus, developed by 67 experts across 14 countries under the framework of ESSKA, AOSSM, and AASPT, established that rehabilitation after meniscus repair and reconstruction should follow both time-based and criterion-based milestones rather than being guided by a fixed calendar alone.
Progress is made when the patient meets defined goals in strength, range of motion, balance, and function, not simply when a certain number of weeks have passed.
In the first two weeks after allograft transplantation, weight-bearing is typically restricted to partial loading with crutches, and the knee is kept in a range of motion brace. Full weight-bearing is usually permitted by six weeks, and range of motion exercises are progressed progressively to restore full flexion. At three to four months, strengthening work intensifies with particular focus on the quadriceps, hamstrings, and hip stabilizers, all of which protect the reconstructed meniscus from excessive compressive and shear forces.
Running typically resumes between four and six months. Return to competitive sport, if pursued, is generally targeted between nine and twelve months, following a structured return-to-sport progression that includes objective strength testing and movement quality assessment.
Recovery from scaffold implantation follows a broadly similar trajectory, though the timeline can be somewhat shorter in cases without concurrent procedures. Research confirms that the Lysholm and IKDC scores of scaffold patients improve significantly and durably over follow-up periods extending beyond five years in the published literature.
However, the consensus is also clear that rehabilitation quality directly influences surgical outcomes, and inadequate physiotherapy after either procedure is associated with higher rates of graft stress, failure, and patient dissatisfaction.
- Weeks 0 to 2: Partial weight bearing, crutches, brace, range of motion exercises begin gently
- Weeks 2 to 6: Progressive weight bearing, brace weaning, early closed-chain strengthening
- Months 2 to 4: Full weight bearing, cycling, pool-based exercise, proprioception work
- Months 4 to 6: Strengthening intensifies, jogging introduced when strength criteria met
- Months 6 to 9: Running, lateral movement, sport-specific drills, ongoing strength testing
- Months 9 to 12: Return to competitive sport if objective milestones achieved and surgeon clears
Like all orthopaedic surgical procedures, meniscal replacement carries risks that patients must understand before consenting. The most common complication after allograft transplantation is tearing of the transplanted meniscal tissue, which accounts for the majority of reoperations. Reoperation rates after MAT are estimated at around 32 percent, with the most frequent cause being a new tear in the allograft.
Other complications include graft extrusion, failure of bone fixation, joint stiffness, infection, and in rare cases, disease transmission from the donor tissue, though the latter is extremely rare with modern tissue banking protocols.
For scaffold implants, failure rates in the published literature range from 6.5 percent for CMI to approximately 18 percent for Actifit at medium-term follow-up, though definitions of failure vary between studies. High-quality randomized controlled trial data remains limited for both scaffold types, and many published series include concurrent procedures that make it difficult to attribute outcomes specifically to the scaffold itself.
Patients should also be aware that even a successful meniscal replacement does not restore the knee to its pre-injury state.
The goal is to reduce pain, improve function, slow the progression of cartilage damage, and extend the window before total knee replacement becomes necessary. Even when the MAT procedure is technically successful, there remain meaningful possibilities that the patient will not be able to return to high-impact sporting activities at the previous level. Patients with physically demanding occupations or high athletic ambitions should discuss these expectations carefully with their surgeon before proceeding.
Research in meniscal replacement is moving on several fronts simultaneously. The most exciting near-term development is the expanded use of fresh, viable cell meniscal allografts rather than standard fresh-frozen tissue.
Fresh grafts preserve living fibrochondrocytes within the transplanted meniscal tissue, and preclinical and early clinical data suggest these cells survive transplantation and contribute to ongoing graft remodeling and maintenance.
The University of Missouri study referenced above reported a 91 percent success rate with fresh grafts, and while the follow-up period is still relatively short, this approach has genuine potential to improve long-term outcomes beyond what frozen allograft alone has achieved.
Tissue engineering approaches are advancing in parallel. Researchers are developing bioengineered scaffolds seeded with the patient's own stem cells or chondrocytes, aiming to create an implant that remodels more completely into native-quality fibrocartilage. Three-dimensional printing allows for anatomically precise scaffold geometry matched to MRI data from the individual patient, rather than the population-averaged geometry of current commercial implants.
Gene therapy approaches to enhance healing and cartilage preservation within the meniscal environment remain at an earlier stage but are being actively investigated. The field is not static, and the outcomes achievable a decade from now may look meaningfully different from those reported in current literature.
For patients navigating a diagnosis of significant meniscal tissue loss today, the central message from the evidence is that replacement surgery, performed by experienced orthopaedic surgeons in appropriately selected patients, produces real and durable benefits.
It is not a cure, and it is not a guarantee of return to any particular activity. But it is a well-validated intervention that significantly delays the joint degradation that would otherwise occur, and for patients who are too young for joint replacement and too symptomatic to function without intervention, it offers a meaningful and evidence-based middle path between doing nothing and replacing the whole knee.
This article is intended for general informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. The information presented here is based on peer-reviewed research available at the time of publication and is not a substitute for professional medical evaluation by a qualified orthopaedic surgeon or healthcare provider.
Meniscal replacement surgery involves individual clinical variables that cannot be assessed through an article. Eligibility, surgical technique, implant selection, rehabilitation protocol, and expected outcomes vary significantly between patients and must be determined through direct clinical consultation with a licensed medical professional.
If you are experiencing knee pain, joint instability, or symptoms following a previous meniscal procedure, please consult a qualified orthopaedic specialist. Do not delay seeking medical advice on the basis of information contained in this article. World At Net does not endorse any specific surgeon, surgical facility, implant manufacturer, or treatment protocol.
.jpg)
.jpg)
.jpg&description=Meniscus Replacement: What the Procedure Involves, Who It Helps, and What Research Actually Shows){kind=link}
0 Comments